Eli Lilly Patents – Insights & Stats (Updated 2024)

Eli Lilly has a total of 9234 patents globally, out of which 3500 have been granted. Of these 9234 patents, more than 66% patents are active. United States of America is where Eli Lilly has filed the maximum number of patents, followed by Japan and Europe. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Eli Lilly.

Eli Lilly was founded in the year 1876. The Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.

Do read about some of the most popular patents of Eli Lilly which have been covered by us in this article and also you can find Eli Lilly patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Eli Lilly patent portfolio.

How many patents does Eli Lilly have?

Eli Lilly has a total of 9234 patents globally. These patents belong to 1617 unique patent families. Out of 9234 patents, 6122 patents are active.

How Many Patents did Eli Lilly File Every Year?

Eli Lilly Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantEli Lilly Applications FiledEli Lilly Patents Granted
2024104440
2023673846
20221318666
202111009
202076556
201959236
201853232
201738762
201628960
201517279
201411995
20135594

How many Eli Lilly patents are Alive/Dead?

Eli Lilly Patent Portfolio

How Many Patents did Eli Lilly File in Different Countries?

Eli Lilly Worldwide Patent Filing

Countries in which Eli Lilly Filed Patents

CountryPatents
United States Of America889
Japan734
Europe707
Australia541
China466
Canada386
Israel282
Hong Kong (S.A.R.)255
Mexico245
Brazil245
Germany227
South Korea221
India204
Taiwan187
Spain171
South Africa171
Singapore149
New Zealand123
Austria112
Korea (South)103
Argentina100
Chile92
Denmark90
Pakistan90
Africa86
Portugal83
Poland82
Saudi Arabia78
Indonesia75
Italy74
Peru70
Malaysia67
Slovenia64
Colombia62
Viet Nam62
Hungary58
Ecuador57
Norway55
United Kingdom54
Cyprus54
Costa Rica50
Croatia44
Philippines44
Tunisia43
Dominican Republic41
Serbia38
Ukraine36
Lithuania35
Macao34
Jordan32
Slovakia30
Morocco30
Russia24
Finland22
Trinidad And Tobago21
Panama21
Thailand20
Czech Republic20
Eurasian Patent Organization19
Kenya19
Malta13
Republic Of Moldova13
Lebanon10
Turkey10
Albania9
Luxembourg8
Uruguay8
Estonia8
El Salvador7
Netherlands7
Montenegro6
Iceland5
Georgia5
Greece5
Egypt4
Bulgaria4
Gulf Cooperation Council3
Kazakhstan3
Ireland2
Belgium2
United Arab Emirates1
Botswana1
Nicaragua1
Romania1
Guatemala1
North Macedonia1
Mongolia1
Cuba1
Belarus1
Uzbekistan1
Latvia1
Algeria1
Honduras1
Brunei1

Where are Research Centres of Eli Lilly Patents Located?

R&D Centers of Eli Lilly

10 Best Eli Lilly Patents

WO2005070963A1 is the most popular patent in the Eli Lilly portfolio. It has received 736 citations so far from companies like Xencor Inc, Macrogenics Inc and Medimmune Llc.

Below is the list of 10 most cited patents of Eli Lilly:

Publication NumberCitation Count
WO2005070963A1736
US20040002587A1587
WO2005113556A1568
US20040102804A1538
WO2001027160A1394
US6241740B1364
US6800620B2324
US6527786B1320
US7288096B2318
US20020103345A1307

Lilly’s major accomplishments include becoming the first business to mass-produce Jonas Salk’s polio vaccine and insulin. Prozac, Dolophine, Cymbalta , and Zyprexa are all produced by Lilly, which is presently the largest maker of psychiatric drugs.

In 2020, the need for digital health adoption accelerated, owing in part to the COVID-19 pandemic. HCPs are urging persons with chronic illnesses to use digital services such as telehealth to continue their care when social distance and stay-at-home orders are in place, for example.

In an early-stage feasibility study, Lilly collaborated with Apple, Inc. and Evidation Health to show that an iPhone, Apple Watch, iPad, and the Beddit sleep monitoring device, in combination with digital apps, can distinguish people with mild cognitive impairment (MCI) and mild Alzheimer’s disease dementia.

Migraine pain can be so severe that in a survey recently released by Eli Lilly and Company, respondents in a survey performed by Nielsen for Eli Lilly and Company rated the worst migraine pain higher than the pain associated with kidney stones and fractured bones.

There were no migraine-specific preventive medications available until recently. Existing treatments were either difficult to tolerate or ineffective for many people. With the introduction of CGRP inhibitors, this is changing. This novel medication prevents the absorption of calcitonin gene-related peptide, or CGRP, a protein linked to migraines caused by inflammation.

EXCLUSIVE INSIGHTS COMING SOON!

What are Eli Lilly’s key innovation segments?

What Technologies are Covered by Eli Lilly?

The chart below distributes patents filed by Eli Lilly in different countries on the basis of the technology protected in patents. It also represents the markets where Eli Lilly thinks it’s important to protect particular technology inventions.

R&D Focus: How Eli Lilly search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Eli Lilly?

Related Articles

Xiamen Easo Patents – Insights & Stats (Updated 2024)

Xiamen Easo has a total of 681 patents globally, out of which 536 have been granted. Of these 681 patents, more than 59% patents are active. China is where Xiamen Easo has filed the maximum number of patents, followed by United States of America and Europe (EPO). Parallelly, China seems

Read More »

Was this article helpful?

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.